close
close

AstraZeneca completes acquisition of Amolyt Pharma

Posted on by darion

Therapeutic peptide Eneboparatide binds to the parathyroid hormone receptor. Source: Prostock-studio/Shutterstock.

AstraZeneca has completed the acquisition of Amolyt Pharma, a company specializing in the treatment of rare endocrine diseases.

The agreement between the parties was announced in March 2024.

AstraZeneca made a payment of $1.05 billion for all outstanding shares of Amolyt Pharma, on a cash and debt free basis.

The transaction includes an upfront payment of $800 million and an additional payment of $250 million contingent upon the achievement of certain regulatory milestones.

This strategic move strengthens AstraZeneca’s late-stage pipeline within its Alexion Rare Diseases business and adds investigational peptide therapeutic eneboparated (AZP-3601) to the company’s bone metabolism portfolio.

Eneboparatide is in Phase III development for the treatment of hypoparathyroidism and binds to the parathyroid hormone (PTH) receptor with high affinity.

Get access to the most comprehensive company profiles on the market, powered by GlobalData. Save hours of research. Gain a competitive advantage.

Company Profile – Free Sample

Your download email will arrive shortly

We are confident in the exceptional quality of our company profiles. However, we want you to make the best decision for your business, which is why we offer a free sample that you can download by submitting the form below

By GlobalData







Please visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information about your rights in relation to your personal data and how you can opt out of future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address provided is your corporate email address.

Hypoparathyroidism is a rare disease characterized by a deficiency of PTH, which causes low calcium levels and elevated phosphorus levels in the blood.

The clinical manifestations of this disease concern tissues and organ systems, especially the kidneys and bones.

Eneboparatide is a subcutaneously administered parathyroid hormone receptor-1 agonist used to treat hypoparathyroidism.

The goals of treatment are to regulate serum calcium levels, alleviate symptoms of hypoparathyroidism, reduce urinary calcium excretion, and potentially prevent deterioration of renal function and chronic kidney disease.

The short plasma half-life may help normalize bone turnover and maintain bone health.

Another candidate in Amolyt’s developmental phase is AZP-3813, a growth hormone peptide receptor antagonist being developed as a potential adjunct to somatostatin analogues in the treatment of acromegaly, a condition associated with inappropriately high growth hormone secretion.

AstraZeneca’s rare disease portfolio generated global sales of $7.76 billion in 2023, according to the company’s fourth-quarter financial reports.